Evidence map›Paper›PMID 30518027›Full record

ReviewInternational journal of molecular sciences2018

A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy.

Min Woo Kim, Seung-Hae Kwon, Jung Hoon Choi, Aeju Lee

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. miRNA: A Promising Therapeutic Target in Cancer.International journal of molecular sciences · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Min Woo KimInternational Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Kumamoto 860-8555, Japan. minwoo-kim@kumamoto-u.ac.jp.ORCID 0000-0002-5886-099X
Seung-Hae KwonDivision of Bio-imaging, Chuncheon Center, Korea Basic Science Institute (KBSI), Chuncheon 24341, Korea. kwonsh@kbsi.re.kr.
Jung Hoon ChoiDepartment of Anatomy, College of Veterinary Medicine, Kangwon National University, Chuncheon 24341, Korea. jhchoi@kangwon.ac.kr.
Aeju LeeInternational Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Kumamoto 860-8555, Japan. aeju-lee@kumamoto-u.ac.jp.ORCID 0000-0002-4925-1156
Kumamoto University · JPKangwon National University · KRKorea Basic Science Institute · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing new drug delivery systems (DDSs) for safer cancer therapy during pre-clinical and clinical applications still constitutes a considerable challenge, despite advances made in related fields. Lipid-based drug delivery systems (LBDDSs) have emerged as biocompatible candidates that overcome many biological obstacles. In particular, a combination of the merits of lipid carriers and functional polymers has maximized drug delivery efficiency. Functionalization of LBDDSs enables the accumulation of anti-cancer drugs at target destinations, which means they are more effective at controlled drug release in tumor microenvironments (TMEs). This review highlights the various types of ligands used to achieve tumor-specific delivery and discusses the strategies used to achieve the effective release of drugs in TMEs and not into healthy tissues. Moreover, innovative recent designs of LBDDSs are also described. These smart systems offer great potential for more advanced cancer therapies that address the challenges posed in this research area.

Indexed as

Drug Delivery SystemsAnimalsBiocompatible MaterialsBiomimeticsDelayed-Action PreparationsHumansLipidsNeoplasmsBiocompatible MaterialsDelayed-Action PreparationsLipidsbiomimeticscancer therapycontrolled releasefunctionalizationlipid-based drug delivery systems

Identifiers

PMID30518027
PMCPMC6321581
OpenAlexW2902532351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.